Summary
Catalepsy—a state of postural immobility (akinesia) with muscular rigidity (rigor)—and reduced locomotion in animals are behavioral deficits showing similarities with symptoms of Parkinson's disease (PD). The effects of the glycine site antagonists 7-chlorokynurenate and (R)-HA-966 on haloperidol-(D2 antagonist) and SCH 23390-(D 1 antagonist) induced catalepsy and reduced locomotion are investigated in rats. Both antagonists dose-dependently counteract dopamine D 2 receptor mediated catalepsy but they have no influence on locomotion. Neither 7-chlorokynurenate nor (R)-HA-966 has any effect on dopamine D 1 receptor mediated catalepsy.
This finding is surprising, since NMDA receptor antagonists counteract both, dopamine D 1 and D 2 receptor mediated catalepsy. D 1 and D 2 receptors are located on different populations of neurons. Thus, the present findings suggest that these different neuronal populations have different sensitivity for ligands binding at the glycine binding site of the NMDA receptor.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Albin RL, Makowiec RL, Hollingsworth ZR, Dure IV LS, Penny JB, Young AB (1992) Excitatory amino acid binding sites in the basal ganglia of the rat: quantitative autoradiographic study. Neuroscience 46/1: 35–48
Alexander GE, DeLong MR, Strick PL (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann Rev Neurosci: 357–381
Bédard PJ, Boucher R, Gomez-Mancilla B, Blandette P (1992) Primate models of Parkinson's disease. In: Boulton A, Baker G, Butterworth R (eds) Neuromethods, vol 21. Animal models of neurological disease, I. Human Press, New York, pp 159–173
Bouyer JJ, Park DH, Joh TH, Pickel VM (1984) Chemical and structural analysis of the relation between cortical inputs and tyrosine hydroxylase-containing terminals in rat striatum. Brain Res 302: 267–276
Bristow LJ, Hutson PH, Thorn L, Tricklebank (1993) The glycine/NMDA receptor antagonist, R-(+)-HA-966, blocks activation of the mesolimbic dopamine system induced by phencyclidine and dizocilpine (MK-801) in rodents. Br J Pharmacol 108: 1156–1163
Bubser M, Keseberg U, Notz PK, Schmidt WJ (1992) Differential behavioral and neurochemical effects of competitive and non-competitive NMDA receptor antagonists in rats. Eur J Pharmacol 229: 75–82
Calderon SF, Sanberg PR, Norman AB (1988) Quinolinic acid lesions of rat striatum abolish D 1- and D2-dopamine receptor-mediated catalepsy. Brain Res 450: 403–407
Carlsson M, Carlsson A (1989) The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 75: 221–226
Colpaert FC (1987) Pharmacological characteristics of tremor, rigidity, and hypokinesia induced by reserpine in rat. Neuropharmacology 26: 1431–1440
Elliott PJ, Close SP, Walsh DM, Hayes AG, Marriott AS (1990) Neuroleptic-induced catalepsy as a model of Parkinson's disease. II. Effects of glutamate antagonists. J Neural Transm [PDSect] 2: 91–100
Gerfen CR, Engber TM, Mahan LC, Sussel Z, Chase TN, Monsma FJ, Sibley DR (1990) D 1 and D 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250: 1429–1432
Graybiel AM (1984) Neurochemically specified subsystems in the basal ganglia. In: Pitman (ed) Functions of the basal ganglia. Ciba Foundation Symposium 107, London, pp 114–149
Harrison MB, Wiley RG, Wooten GF (1992) Changes in D 2 but not D 1 receptor binding in the striatum following a selective lesion of striatopallidal neurons. Brain Res 590: 305–310
Hauber W (1992) Anti-akinetic and anti-bradykinetic effects of NMDA antagonists in a rodent model of Parkinson's disease. In: Elsner N, Richter DW (eds) Rhythmogenesis in neurons and networks — Proceedings of the 20th Göttingen Neurobiology Conference. Thieme, Stuttgart, pp 593
Hauber W, Schmidt WJ (1993) Discrete quinolinic acid lesion of the lateral but not of the medial caudate/putamen reversed haloperidol induced catalepsy in rats. J Neural Transm [Gen Sect] 94: 103–114
Hutson PH, Bristow LJ, Thorn L, Tricklebank MD (1991) R-(+)-HA-966, a glycine/NMDA receptor antagonist, selectively blocks the activation of the mesolimbic dopamine system by amphetamine. Br J Pharmacol 103: 2037–2044
Jolicoeur FB, Rivest R (1992) Rodent models of Parkinson's disease. In: Boulton A, Baker G, Butterworth R (eds) Neuromethods, vol 21. Animal models of neurological disease, I. Human Press, New York, pp 135–158
Klockgether T, Turski L (1990) NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats. Ann Neurol 28: 539–546
Kretschmer BD, Zadow B, Volz TL, Volz L, Schmidt WJ (1992) The contribution of the different binding sites of the N-methyl-D-aspartate (NMDA) receptor to the expression of behavior. J Neural Transm [GenSect] 87: 23–35
Kutsuwada T, Kashiwabuchi N, Mori H, Sakimura K, Kushiya E, Araki K, Meguro H, Masaki H, Kumanishi T, Arakawa M, Mishina M (1992) Molecular diversity of the NMDA receptor channel. Nature 358: 36–41
Monaghan DT, Olverman HJ, Nguyen L, Watkins JC, Cotman CW (1988) Two classes of N-methyl-D-aspartate recognition sites: differential distribution of differential regulation by glycine. Proc Natl Acad Sci USA 85: 9836–9840
Monyer H, Sprengel R, Schoepfer R, Herb A, Higuchi M, Lomeli H, Burnashey N, Sakmann B, Seeburg PH (1992) Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science 256: 1217–1221
Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. Academic Press, Sydney
Rabey JM, Nissipeanu P, Korczyn AD (1992) Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J Neural Transm [P-D Sect] 4: 277–282
Robertson GS, Vincent SR, Fibiger HC (1992) D 1 and D 2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopallidal neurons. Neuroscience 49/2: 285–296
Ross RT (1990) Drug-induced Parkinsonism and other movement disorders. Can J Neurol Sci 17: 155–162
Sakurai SY, Penny JB, Young AB (1993) Regionally distinct N-methyl-D-aspartate receptors distinguished by quantitative autoradiography of [3H]MK-801 binding in rat brain. J Neurochem 60: 1344–1353
Sanberg PR, Bunsey MD, Giordano M, Norman AB (1988) The catalepsy test its ups and downs. Behav Neurosci 102: 748–759
Scheel-Krüger J (1983) The GABA receptor and animal behavior—evidence that GABA transmits and mediates dopaminergic functions in the basal ganglia and the limbic system. In: Enna SJ (ed) The GABA receptors. The Human Press, New Jersey, pp 215–256
Schmidt WJ, Bubser M (1989) Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacol Biochem Behav 32: 621–623
Schmidt WJ, Bubser M, Hauber W (1990) Anticataleptic effects of NMDA receptor antagonists. Eur J Neurosci [Suppl 3]: 118
Schmidt WJ, Zadow B, Kretschmer BD, Hauber W (1991) Anticataleptic potencies of glutamate-antagonists. Amino Acids 1: 225–237
Smith AD, Bolam JP (1990) The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci 13/7: 259–265
Standaert DG, Testa CM, Penny JB, Young AB (1993) Alternatively spliced isoforms of the NMDA-R 1 glutamate receptor subunit: differential expression in the basal ganglia of the rat. Neurosci Lett 152: 161–164
Surmeier DJ, Eberwine J, Wilson CJ, Cao A, Stefani A, Kitai ST (1992) Dopamine receptor subtypes colocalize in rat striatonigral neurons. Proc Natl Acad Sci USA 89: 10178–10182
Verma A, Kulkarni SK (1992) D1/D2 dopamine and N-methyl-D-aspartate (NMDA) receptor participation in experimental catalepsy in rats. Psychopharmacology 109: 477–483
Wachtel H (1991) Antiparkinsonian dopamine agonists: a review of the pharmacokinetics and neuropharmacology in animal and humans. J Neural Transm [P-D Sect] 3: 151–201
Wroblewski JT, Danysz W (1989) Modulation of glutamate receptors. Molecular mechanism and functional implications. Ann Rev Pharmacol Toxicol 29: 441–474
Yoshida Y, Ono T, Kizu A, Fukushima R, Miyagishi T (1991) Striatal N-methyl-D-aspartate receptors in haloperidol-induced catalepsy. Eur J Pharmacol 203: 173–180
Zahm DS, Brog JS (1992) On the significance of subterritories in the “accumbens” part of the rat ventral striatum. Neuroscience 50/4: 751–767
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kretschmer, B.D., Winterscheid, B., Danysz, W. et al. Glycine site antagonists abolish dopamine D 2 but not D 1 receptor mediated catalepsy in rats. J. Neural Transmission 95, 123–136 (1994). https://doi.org/10.1007/BF01276431
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01276431